Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia.
So far, gestational diabetes treated with tolbutamide has never been associated with severe hypoglycaemia in the newborn when the mother's diabetes was well controlled. We report a case of a premature neonate, gestational age 34 weeks, with severe and long-standing hypoglycaemia from birth. The mother had well-controlled gestational diabetes, treated with tolbutamide from the 24th week of gestation until delivery. The neonate had inappropriately high levels of serum proinsulin, insulin and C-peptide relative to blood glucose concentrations. From day 19 after birth, the levels were normalized. Serum tolbutamide was 140.6 micromol/l (38 microg/ml) at 3 h after birth. Zero-order kinetics were seen during the first 90 postnatal hours. The half-life of serum tolbutamide decreased from 46 to 6 h. It is suggested that tolbutamide, when given to the mother until delivery, may cause severe and prolonged hyperinsulinaemic hypoglycaemia in premature neonates. The initially prolonged tolbutamide half-lives and zero-order kinetics suggest immaturity of hepatic elimination during the first 2 days of postnatal life.
Christesen
H B
HB
Department of Paediatrics, Odense University Hospital, Denmark.
Melander
A
A
D000328:Adult; D016640:Diabetes, Gestational / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006801:Humans; D006946:Hyperinsulinism / Q000139:chemically induced* / Q000652:urine; D007003:Hypoglycemia / Q000139:chemically induced* / Q000652:urine; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000652:urine; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000139:chemically induced* / Q000652:urine; D016014:Linear Models; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D014044:Tolbutamide / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000652:urine
D007004:Hypoglycemic Agents; D014044:Tolbutamide